Scinai Immunotherapeutics Signs Binding Option to Acquire Italian Biotech Pincell

• Scinai Immunotherapeutics Ltd. has signed a binding option agreement to acquire Italian biotech firm Pincell srl, expanding its pipeline in dermatological treatments.

• The companies have applied for a €12 million EU grant to support the development of PC111, a monoclonal antibody targeting severe skin blistering disorders.

Scinai Immunotherapeutics Ltd., a biopharmaceutical company focused on inflammation and immunology (I&I) biological products and contract manufacturing, has signed a binding option agreement to acquire Italian biotech firm Pincell srl. The agreement aligns with Scinai’s strategy to advance novel therapies for severe skin disorders.

As part of the acquisition process, a wholly owned Polish subsidiary of Scinai has submitted a €12 million grant application under the European Funds for a Modern Economy (FENG) program. If approved, the funding will support the development of PC111, Pincell’s fully human monoclonal antibody that targets the Fas/FasL pathway. The decision on the grant is expected by mid-July to early August, pending Italian regulatory clearances.

PC111 is designed to block the activation of apoptosis in skin cells, a mechanism implicated in severe blistering conditions such as pemphigus, Stevens-Johnson Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN). Unlike traditional immunosuppressive treatments, PC111 aims to mitigate disease progression without compromising immune function. Pincell’s preclinical studies indicate that the antibody could serve as a novel targeted therapy for these conditions.

“We are truly excited to have the opportunity to acquire Pincell and develop, in collaboration with the Pincell team, PC111 to treat these devastating skin disorders,” said Amir Reichman, CEO of Scinai Immunotherapeutics. He highlighted Pincell’s expertise in dermatological research and the potential for non-dilutive funding to support clinical development.

Pincell’s Chairman and CEO, Dr. Antonino Amato, expressed confidence in the partnership, noting that Scinai Immunotherapeutics’ expertise in biologics development and manufacturing will complement Pincell’s research capabilities. If successful, the acquisition could accelerate the availability of PC111 for patients with high unmet medical needs.